Clene rises on positive data from ALS therapy study

Clene

29/08/2023 16:05

** Shares of drug developer Clene  CLNN.O  rise 3.3% to 72
cents
    ** Company says its therapy, CNM-Au8, in a mid-stage trial
for nervous system disease amyotrophic lateral sclerosis (ALS),
shows a significant survival benefit of 19.3 months in 45
participants
    ** Results also find 52% significant decreased risk of ALS
clinical worsening events using the treatment
    ** Shares down 30.3% YTD

 (Reporting by Purvi Agarwal)
 ((Purvi.Agarwal@thomsonreuters.com;))